Ranibizumab
Cimerli is a brand-name biosimilar medication referencing ranibizumab, used to treat certain eye conditions affecting the retina. It is prescribed for adults with wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. As an anti-VEGF agent, it helps reduce fluid leakage and abnormal blood vessel growth in the eye.
Cimerli is an eye injection biosimilar used to treat various retinal conditions including wet AMD and diabetic eye disease by inhibiting abnormal blood vessel growth.
Key facts at a glance
- RxNorm
- 2612677
- Generic
- Cimerli
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treats wet (neovascular) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. It is administered as an intravitreal injection by an eye care professional.
Cimerli is a biosimilar referencing ranibizumab. It is a fragment of a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting VEGF from binding to its receptors. This reduces vascular permeability and suppresses abnormal blood vessel growth in the retina.
Cimerli is FDA-approved as a biosimilar to Lucentis. Common side effects may include eye redness, pain, floaters, and increased intraocular pressure. Serious infections or retinal detachment are rare but possible. Patients should discuss their complete medical history with their eye doctor before treatment, including any current infections or pregnancy considerations.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy